解剖学报

解剖学报 ›› 2019, Vol. 50 ›› Issue (5): 608-612.doi: 10.16098/j.issn.0529-1356.2019.05.011

• 肿瘤生物学 • 上一篇    下一篇

膀胱尿路上皮癌中候选生物标志物转录因子21的甲基化机制及意义

丁小明1 许嵘2* 张文州2 谢志新2   

  1. 1.泉州医学高等专科学校基础医学部解剖学系，福建 泉州 362011; 2.泉州医学高等专科学校药学院，福建 泉州 362011
  • 收稿日期:2018-10-12 修回日期:2019-05-15 出版日期:2019-10-06 发布日期:2019-12-10
  • 通讯作者: 许嵘 E-mail:179533609@qq.com
  • 基金资助:
    2016年福建省中青年教师教育科研项目

Methylation mechanism of candidate biomarker transcription factor 21 in bladder urothelial carcinoma

DING Xiao-ming1 XU Rong 2* ZHANG Wen-zhou2 XIE Zhi-xin 2   

  1. 1.Department of Anatomy,Faculty of Basic Medicine, Quanzhou Medical College, Fujian Quanzhou 362011,China; 2.School of Pharmacy, Quanzhou Medical College, Fujian Quanzhou 362011, China
  • Received:2018-10-12 Revised:2019-05-15 Online:2019-10-06 Published:2019-12-10
  • Contact: XU Rong E-mail:179533609@qq.com

PDF

摘要：

目的 探讨膀胱尿路上皮癌中候选生物标志物转录因子21（TCF21）甲基化的意义。 方法 选择2016年10月~2017年10月间疑似膀胱癌患者142例，其中经病理学检测确诊为膀胱癌80例为研究组，经病理学检测确诊为非膀胱癌共62例为对照组。另选择同期进行体检的健康者尿标本40例作为健康组。检测研究组膀胱癌组织、癌旁组织、对照组病灶组织中TCF21甲基化水平，并检测研究组、对照组和健康组尿液中TCF21甲基化水平，分别比较膀胱癌组织、尿液中TCF21甲基化水平与临床病理特点间的关系，并分析两者对于膀胱癌的诊断效能。 结果 膀胱癌组织TCF21甲基化水平显著高于癌旁组织和对照组（P<0.05），研究组尿液TCF21甲基化水平显著高于对照组和健康组（P<0.05）。男性、年龄>60岁、高的TNM分期和高分级的膀胱癌患者膀胱癌组织和尿液中TCF21甲基化水平更高（P<0.05）。膀胱癌组织与尿液中TCF21甲基化水平对膀胱癌均有较高的诊断意义，且两者的诊断意义差异无显著性（P>0.05）。 结论 TCF21基因在膀胱癌组织和膀胱癌患者尿液中均具有较高的甲基化水平，并且与病理特点相关，膀胱癌组织和膀胱癌患者尿液对于膀胱癌均具有较高的诊断意义。

关键词: 膀胱癌, 表观遗传, 转录因子21, 焦磷酸测序技术, 人

Abstract:

Objective To explore the significance of methylation of the candidate biomarker transcription factor 21(TCF21) in bladder urothelial carcinoma. Methods From October 2016 to October 2017, 142 patients with suspected bladder cancer were selected. Among them, 80 were diagnosed as bladder cancer by pathological examination as the study group. A total of 62 non-bladder cancers were diagnosed by pathological examination as the control group. In addition, 40 healthy urine specimens during the same period were selected as the healthy group. Detected and compared the methylation of TCF21 in bladder cancer tissues, paracancerous tissues, and control tissues of the study group, and detected and compared the TCF21 methylation levels in urine of study group, control group, and healthy group. The relationship between TCF21 methylation level and clinicopathological features was explored, and the diagnostic efficacy of both for bladder cancer was analyzed. Results The methylation level of TCF21 in bladder cancer tissue was significantly higher than that in the adjacent tissue and control group (P<0.05). The methylation level of urinary TCF21 in the study group was significantly higher than that in the control and healthy groups (P<0.05). TCF21 methylation levels in bladder cancer tissues and urine were higher in men, ages>60 years, high TNM stages, and high grade bladder cancer patients (P<0.05). TCF21 methylation levels in bladder cancer tissues and urine hadhigher diagnostic efficacy for bladder cancer, and there was no significant difference in the diagnostic efficacy between the two groups (P>0.05). Conclusion TCF21 gene hasd high methylation level in urine of patients with bladder cancer and bladder cancer, and is associated with pathological features. Urinary bladder cancer tissues and urine have higher diagnostic efficacy for bladder cancer.

Key words: Bladder carcinoma, Epigenetics, Transcription factor 21, Pyrosequencing, Human